Marrow sensitization to 5-fluorouracil using the ligands for Flt-3 and c-Kit

Experimental Hematology

Volumn 27, Issue 3, 1999, Pages 520-525

  Jin, Liqing ^a   Neff, Tobias ^a   Blau, C Anthony ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

C kit ligand; Flt3 ligand; Marrow sensitization; Progenitors

Indexed keywords

FLT3 LIGAND; FLUOROURACIL; STEM CELL FACTOR;

ANIMAL CELL; ARTICLE; CELL CLONE; CELL PROTECTION; COLONY FORMING UNIT C; CYTOPATHOGENIC EFFECT; DRUG TOLERANCE; FEMALE; GROWTH REGULATION; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BONE MARROW; CELL COUNT; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FEMUR; FLUOROURACIL; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELLS; MEMBRANE PROTEINS; MICE; ORGAN SPECIFICITY; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; SPLEEN; STEM CELL FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

ANIMALIA;

EID: 0033024609     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(98)00039-3     Document Type: Article

References (31)

1. Emerson S.G. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells. the next generation of cellular therapeutics Blood. 87:1996;3082.
2. Bodine D.M., Seidel N.E., Zsebo K.M., Orlic D. In vivo administration of stem cell factor to mice increases the absolute number of pluripotent hematopoietic stem cells. Blood. 82:1993;445.
3. Bodine D.M., Seidel N.E., Orlic D. Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood. 88:1996;89.
4. Molineux G., Migdalska A., Haley J., Evans G.S., Dexter T.M. Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil. Blood. 83:1994;3491.
5. Van Os R., Dawes D., Mislow J.M., Witsell A., Mauch P.M. Host conditioning with 5-fluorouracil and kit-ligand to provide for long-term bone marrow engraftment. Blood. 89:1997;2376.
6. Harrison D.E., Zsebo K.M., Astle C.M. Splenic primitive hematopoietic stem cell (PHSC) activity is enhanced by steel factor because of PHSC proliferation. Blood. 83:1994;3146.
7. Neta R., Keller J.R., Ali N., Blanchette F., Dubois C.M. Contrasting mechanisms of the myeloprotective effects of interleukin-1 against ionizing radiation and cytotoxic 5-fluorouracil. Radiat Res. 145:1996;624.
8. Barker J., Compton S. Hematopoietic repopulation of adult mice with β-thalassemia. Blood. 83:1994;828.
9. Matthews W., Jordan C.T., Wiegand G.W., Pardoll D., Lemischka I.R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 65:1991;1143.
10. Mackarehtschian K., Hardin J.D., Moore D.A., Boast S., Goff S.P., Lemischka I.R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 3:1995;147.
11. Lyman S.D., James L., Vanden Bos T., deVries P., Brasel K., Gliniak B., Hollingsworth L.T., Picha K.S., McKenna H.J., Splett R.R., Fletcher F.A., Maraskovsky E., Farrah T., Foxworthe D., Williams D.E., Beckmann M.P. Molecular cloning of a ligand for the flt3/flk2 tyrosine kinase receptor. A proliferative factor for primitive hematopoietic cells Cell. 75:1993;1157.
12. Hannum C., Culpepper J., Campbell D., McClanaha T., Zurawski S., Bazan J.F., Kastelein R., Hudak S., Wagner J., Mattson J., Luh J., Duda G., Martina N., Peterson D., Menon S., Shanafelt A., Muench M., Kelner G., Namikawa R., Rennick D., Roncarolo M.-G., Zlotnik A., Rosnet O., Dubreuil P., Birnbaum D., Lee F. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 368:1994;643.
13. Hudak S., Hunte B., Culpepper J., Menon S., Hannum C., Thompson-Snipes L., Rennick D. FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood. 85:1995;2747.
14. Yonemura Y., Ku H., Lyman S.D., Ogawa M. In vitro expansion of hematopoietic progenitors and maintenance of stem cells. comparison between FLT3/FLK-2 ligand and KIT ligand Blood. 89:1997;1915.
15. Jacobsen S.E., Okkenhaug C., Myklebust J., Veiby O.P., Lyman S.D. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro. synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors J Exp Med. 181:1995;1357.
16. Muench M.O., Roncarolo M.-G., Menon S., Xu Y., Kastelein R., Zurawski S., Hannum C., Culpepper J., Lee F., Namikawa R. FLK2/FLT3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood. 85:1995;963.
17. Gabbianelli M., Pelosi E., Montesoro E., Valtieri M., Luchetti L., Samoggia P., Vitelli L., Barberi T., Testa V., Lyman S., Peschle C. Multilevel effects of flt3 ligand on human hematopoiesis. expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursor Blood. 86:1995;1661.
18. McKenna H.J., de Vries P., Brasel K., Lyman D.S., Williams D.E. Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. Blood. 86:1995;341.
19. Petzer A.L., Zandstra P.W., Piret J.M., Eaves C.J. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells. novel responses to flt3-ligand and thrombopoietin J Exp Med. 183:1996;2551.
20. Brasel K., McKenna H.J., Morrissey P.J., Charrier K., Morris A.E., Lee C.C., Williams D.E., Lyman S.D. Hematologic effects of FLT3 ligand in vivo in mice. Blood. 88:1996;2004.
21. Papayannopoulou Th Nakamoto B., Andrews R.G., Lyman S.D., Lee M.Y. In vivo effects of flt3/flk2 ligand on mobilization of hematopoietic progenitors in primartes and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood. 90:1997;620.
22. Molineux G., McCrea C., Yan X.Q., Kerzic P., McNiece I. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood. 89:1997;3998.
23. Costa J.J., Demetri G.D., Harrist T.J., Dvorak A.M., Hayes D.F., Merica E.A., Menchaca D.M., Gringeri A.J., Schwartz L.B., Galli S.J. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med. 183:1996;2681.
24. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., McKenna H.J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice. multiple dendritic cell subpopulations identified J Exp Med. 184:1996;1953.
25. Lynch D.H., Andreasen A., Maraskovsky E., Whitmore J., Miller R.E., Schuh J.C. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med. 3:1997;625.
26. Blau C.A., Neff T., Papayannopoulou Th The hematological effects of folate analogues. implications for using the dihydrofolate reductase gene for in vivo selection Hum Gene Ther. 7:1996;2069.
27. Motulsky HJ (1994-1995) GraphPad PRISM version 2.0, Users Guide. GraphPad Software Inc.: San Diego, CA.
28. Blau C.A., Neff T., Papayannopoulou T. Cytokine prestimulation as a gene therapy strategy. implications for using the MDR 1 gene as a dominant selectable marker Blood. 89:1997;146.
29. Roberts A.W., Metcalf D. Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. Blood. 86:1995;1600.
30. Uchida N., He D., Friera A.M., Reitsma M., Sasaki D., Chen B., Tsukamoto A. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood. 89:1997;465.
31. Morrison S.J., Wright D.E., Weissman I.L. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA. 94:1997;1908.